Inbiomotion and Source BioScience sign an exclusive agreement for MAF Test® in United Kingdom and Ireland

by Ysios Capital

Source BioScience, an industry-leading provider of genomic services and healthcare diagnostics, and Inbiomotion, a company commercializing its proprietary MAF Test® for identifying high risk early-st...

Read more

Inbiomotion and The Scientific Group sign an exclusive distribution agreement of MAF Test® for the Sub-Saharan Africa

by Ysios Capital

This pioneering test aids oncologists in predicting recurrence and survival rates in breast cancer patients and potential treatment eligibility to bisphosphonates

Read more

IRB Barcelona spin-off Inbiomotion’s MAF Test® selects breast cancer patients

by IRB Barcelona - Instituto de Investigación Biomédica

IRB Barcelona spin-off Inbiomotion’s MAF Test® selects breast cancer patients benefitting from adjuvant clodronate, significantly improving their overall survival

Read more
Subscribe to Directory
Write an Article

Recent News

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Más de 1.500 cambios epigenéticos en e...

Un equipo de investigadores de la Universidad Juli...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Remedi is born from the fusion of the co...

by Regenera Activa Worldwide

Regenera Activa Worldwide and Rigenera HBW, biotech firms specializing...

Photos Stream